Spoken Alpha
INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals designs DNA medicines and electroporation delivery devices to treat HPV-related diseases, cancers, and infectious diseases. The company's lead candidate, INO-3107, is a DNA immunotherapy for recurrent respiratory papillomatosis (RRP) that teaches the body's cells to produce proteins targeting HPV-infected cells.
INOVIO PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $120.5M market cap.
INO beat consensus EPS by 0.7% in Q2 FY2026, reported Aug 11, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for INO.
$ curl https://api.spokenalpha.com/v1/companies/INOFAQ
Spoken Alpha indexes INO's earnings call transcripts at https://spokenalpha.com/companies/INO. Each call links to attributed speakers and parsed analyst Q&A. INOVIO PHARMACEUTICALS, INC.'s own investor relations page is at https://ir.inovio.com/overview/default.aspx.
INOVIO PHARMACEUTICALS, INC. (INO) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
INOVIO PHARMACEUTICALS, INC. (INO) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.07 | $-0.25 | +72.0% | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.31 | $-0.33 | +6.1% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-12 | $-0.28 | $-0.34 | +19.6% | $-65.3K | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.87 | $-0.48 | -81.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.61 | $-0.62 | +1.6% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.51 | $-0.74 | +31.1% | $65.3K | — | — | EODHD |
| Q4 FY2024 | 2025-03-03 | $-0.60 | $-0.83 | +27.9% | $117.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.89 | $-1.13 | +21.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-1.19 | $-1.10 | -8.2% | $100.8K | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-1.31 | $-0.99 | -32.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-05 | $-1.12 | $-1.27 | +11.8% | $102.7K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-1.56 | $-1.50 | -4.0% | $388.4K | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-1.56 | $-1.72 | +9.3% | $226.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-1.92 | $-1.80 | -6.7% | $114.9K | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-0.21 | $-0.17 | -23.5% | $124.7K | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-1.80 | $-3.27 | +45.0% | $9.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-5.52 | $-3.52 | -56.8% | $784.4K | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-4.32 | $-3.93 | -9.9% | $199.1K | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.50 | $-0.32 | -56.3% | $839.1K | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-3.48 | $-3.62 | +3.9% | $291.7K | — | — | EODHD |
Source: EODHD. INO reported actuals as published; sparse fields render as —.